Data / Drug companies / Alvogen Inc.
Alvogen Inc.: 85 products in the FDA NDC directory, labeler code 47781
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Alvogen Inc. (labeler code 47781) lists 85 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 85 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 18, 2025.
The request: Watch Alvogen Inc. (FDA labeler code 47781): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 47781
- Products in commercial distribution
- 85
- Packages
- 112
- Finished drugs by generic name
- 21
- Prescription products
- 85
- Over the counter products
- 0
- Controlled substance products
- Schedule II 36, Schedule III 10
- Flagged as original packager
- 46 of 46 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 9
- Earliest marketing start
- May 3, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 63 | 74.1% |
| New drug applications (NDA) | 18 | 21.2% |
| Authorized generics (NDA) | 4 | 4.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 85 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 31 | 36.5% |
| Capsule | 19 | 22.4% |
| Tablet, extended release | 8 | 9.4% |
| Capsule, extended release | 6 | 7.1% |
| Patch | 5 | 5.9% |
| Injection, solution | 4 | 4.7% |
| Film | 4 | 4.7% |
| Patch, extended release | 4 | 4.7% |
| Tablet, film coated, extended release | 2 | 2.4% |
| Cream | 1 | 1.2% |
| Powder, for suspension | 1 | 1.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sertraline hydrochloride | 47781-962 | Capsule | Authorized generics (NDA) | September 18, 2025 |
| Sertraline hydrochloride | 47781-951 | Capsule | Authorized generics (NDA) | September 18, 2025 |
| Bonsity | 47781-852 | Injection, solution | New drug applications (NDA) | June 6, 2025 |
| Lisdexamfetamine dimesylate | 47781-568 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine dimesylate | 47781-567 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine dimesylate | 47781-566 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine dimesylate | 47781-565 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine dimesylate | 47781-564 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine dimesylate | 47781-563 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lisdexamfetamine dimesylate | 47781-562 | Capsule | Generic drugs (ANDA) | August 25, 2023 |
| Lenalidomide | 47781-487 | Capsule | Generic drugs (ANDA) | March 6, 2023 |
| Lenalidomide | 47781-483 | Capsule | Generic drugs (ANDA) | March 6, 2023 |
| Testosterone cypionate | 47781-911 | Injection, solution | Generic drugs (ANDA) | November 2, 2022 |
| Testosterone cypionate | 47781-910 | Injection, solution | Generic drugs (ANDA) | November 2, 2022 |
| Lenalidomide | 47781-488 | Capsule | Generic drugs (ANDA) | September 3, 2022 |
| Lenalidomide | 47781-486 | Capsule | Generic drugs (ANDA) | September 3, 2022 |
| Lenalidomide | 47781-485 | Capsule | Generic drugs (ANDA) | September 3, 2022 |
| Lenalidomide | 47781-484 | Capsule | Generic drugs (ANDA) | September 3, 2022 |
| Buprenorphine transdermal system | 47781-419 | Patch, extended release | Generic drugs (ANDA) | May 17, 2022 |
| Buprenorphine transdermal system | 47781-408 | Patch, extended release | Generic drugs (ANDA) | May 17, 2022 |
| Buprenorphine transdermal system | 47781-407 | Patch, extended release | Generic drugs (ANDA) | May 17, 2022 |
| Buprenorphine transdermal system | 47781-406 | Patch, extended release | Generic drugs (ANDA) | May 17, 2022 |
| Dexamethasone | 47781-916 | Tablet | Generic drugs (ANDA) | June 28, 2021 |
| Dexamethasone | 47781-914 | Tablet | Generic drugs (ANDA) | June 28, 2021 |
| Hydrocodone Bitartrate | 47781-398 | Tablet, extended release | Generic drugs (ANDA) | March 3, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.